NovaScreen Receives Wyeth Contract for High Throughput Screen
Complete the form below to unlock access to ALL audio articles.
NovaScreen Biosciences Corporation, a Caliper Life Sciences, has announced that Wyeth Pharmaceuticals, a division of Wyeth, has selected NovaScreen to conduct a high-throughput screening campaign.
As a result, NovaScreen will screen 500,000 compounds against an inflammatory target.
The HTS campaign combines NovaScreen's kinase profiling expertise with Caliper's LabChip® 3000 microfluidic screening platform, which utilizes electrophoretic separation of assay components to provide analytical quality data that is highly reproducible.
Performing the screen using LabChip 3000 technology assures data quality that helps eliminate false positives in the primary screen, providing relevant and accurate information.
Accessing the technology through collaboration with NovaScreen provides companies with screening data that shapes their drug discovery efforts by identifying compounds that may get overlooked with other techniques.
"NovaScreen provides another avenue for companies to access Caliper's proven microfluidic technology," said David Manyak, president of NovaScreen Biosciences.
"Pharmaceutical companies can outsource screening projects to NovaScreen to ensure that the highest quality technologies are used without the upfront investment to purchase in-house systems."
